Travacom Post Marketing Surveillance Study

Phase 4

Withdrawn

• Conditions: Open-angle Glaucoma; Ocular Hypertension
• Interventions: Drug: Travoprost/timolol fixed combination (Travacom)

• Registration Number: NCT01510132
• Lead Sponsor: Alcon Research

Brief Summary

The purpose of this multi-center, open label, single arm, post-marketing surveillance study is to assess the safety of Travacom in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to beta-blockers, prostaglandins, or other intraocular pressure-lowering (IOP) medication and when use of Travacom is considered appropriate.

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design

Study Timeline

• Study Start: 2012-01
• Primary Completion: 2012-01
• Study Completion: 2012-01
• Study First Submitted: 2012-01-11
• Study First Submitted QC: 2012-01-11
• Study First Posted: 2012-01-13
• Status Verified: 2012-10
• Last Update Submitted: 2012-10-16
• Last Update Posted: 2012-10-18

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• 18 years of age or older.
• Open-angle glaucoma or ocular hypertension insufficiently responsive to betablockers, prostaglandins, or other intraocular pressure-lowering (IOP) agents and when the use of Travacom is considered appropriate.
• Discontinued use of all other ocular hypotensive medications prior to receiving the study medication for the entire course of the study.
• Mean IOP not greater than 36 mmHG in either eye.
• Read, sign, and date (or legal representative) the Informed Consent prior to the start of any study-related procedures.
• Other protocol-defined inclusion criteria may apply.

Read More

Exclusion Criteria

• Women of childbearing potential (not postmenopausal for at least one year or not surgically sterile) who are currently pregnant, have a positive result on the urine pregnancy test at Screening, intend to become pregnant during the study period, are breastfeeding, or do not agree to use an adequate birth control method to prevent pregnancy throughout the study.
• Chronic, recurrent, or severe inflammatory eye disease, such as scleritis, uveitis, or herpes keratitis.
• History of clinically significant or progressive retinal disease.
• Best corrected visual acuity (BCVA) score worse than 20/80 Snellen.
• Bronchial asthma or related history that would preclude safe administration of a topical beta-blocker.
• Severe, unstable, or uncontrolled cardiovascular, hepatic, or renal disease or related history that would preclude safe administration of a topical beta-adrenergic blocking agent.
• History of spontaneous or current hypoglycemia or uncontrolled diabetes.
• Known medical allergy, hypersensitivity, or poor tolerance to any component of Travacom deemed clinically significant in the opinion of the Principal Investigator.
• Use of any additional topical or system ocular hypotensive medication during the study.
• Participation in any other investigational study within 30 days prior to Screening visit.
• Other protocol-defined exclusion criteria may apply.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Travacom	Travoprost/timolol fixed combination (Travacom)	Travoprost/timolol fixed combination self-administered at the rate of 1 drop per eye, one time a day, at approximately 8 a.m. each day for 8 weeks.

Primary Outcome Measures

Name	Time	Method
Extent of exposure	Up to 8 weeks	Extent of exposure is calculated as days on therapy. Days on therapy is defined as the difference in days between the date of exit (last) instillation as recorded on the last visit and the visit at which medication was first administered.
Adverse events	Up to 8 weeks	Any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the study treatment, whether or not related to the treatment. Adverse events will be collected spontaneously and systematically at each scheduled study visit and may be collected at any unscheduled visit that occurs during the study. Adverse events will be documented on Adverse Events Forms and will be reported by MedDRA preferred terminology.